Azenta(US:AZTA)2026-02-04 14:30Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $149 million, up 1% reported but down 1% organically, with a 2% headwind from foreign exchange [14][16] - Non-GAAP EPS for the first quarter was $0.09, and adjusted EBITDA margin was 8.5%, down approximately 230 basis points year-over-year [15][17] - Free cash flow for the quarter was $15 million, with cash, cash equivalents, and marketable securities totaling $571 million, an increase of $25 million quarter-over-quarter [15][16] Business Line Data and Key Metrics Changes - In Sample Management Solutions, revenue was $81 million, flat on a reported basis and down 2% organically, with growth in biorepositories offset by declines in automated stores and cryo [18][19] - Multiomics revenue was $67 million, up 1% on a reported basis and flat organically, with growth in next-generation sequencing and gene synthesis, but weakness in Sanger sequencing [19][20] - Gross margin for Sample Management Solutions was 45.4%, down 370 basis points year-over-year, primarily due to higher rework costs on automated stores projects [19] Market Data and Key Metrics Changes - Positive momentum was observed in Europe, while North America remained slow, impacted by macroeconomic conditions and a government shutdown [6][8] - China showed strong performance with 26% organic growth in Multiomics, driven by demand in biotech and pharma [20][77] - The overall market conditions are mixed, with cautious capital spending decisions across parts of the life sciences ecosystem [6][8] Company Strategy and Development Direction - The company aims to embed operational excellence, accelerate growth, and expand margins as part of its strategic priorities for 2026 [6][11] - A definitive agreement for the sale of B Medical was announced, expected to close by March 31, 2026, which will sharpen focus on core portfolio and enhance financial flexibility [11][14] - The company is committed to disciplined capital deployment and has a $250 million share repurchase authorization to return value to shareholders [11][16] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about improvements in capital markets and renewed M&A activity, expecting greater clarity around government and academic funding [6][8] - The company anticipates acceleration in the second half of 2026 as delayed approvals are processed and capital investment ramps up [9][13] - Management remains confident in achieving full-year guidance of 3%-5% organic revenue growth and adjusted EBITDA margin expansion of approximately 300 basis points [13][22] Other Important Information - The company continues to focus on operational improvements through the Azenta Business System, which drives measurable improvements in delivery, quality, and productivity [10] - The company is addressing quality issues in automated stores, with remediation efforts expected to be completed by the end of Q2 [19][64] Q&A Session Summary Question: Can you discuss your confidence in getting SMS margins back to desired levels? - Management acknowledged product mix and geo mix causing margin headwinds but expressed confidence in addressing these issues and reiterated guidance for the full year [24][25] Question: What are your expectations for top-line performance in Q2? - Management indicated that while they do not guide quarterly, they expect an uplift in revenue compared to Q1, with significant growth anticipated in the second half of the year [41][42] Question: How are you addressing the quality issues in automated stores? - Management detailed efforts to resolve quality issues and emphasized structural alignment to better serve customers, indicating that they are on track to meet customer needs [64][66] Question: What is the outlook for growth in the pharma and biotech sectors? - Management noted increased clarity and confidence in the pharma and biotech sectors, with ongoing investments and positive conversations with customers [49][50]